Alvotech (OISE:ALVO) Current Accrued Expense: kr10,916 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OISE:ALVO Alvotech OISE:ALVO
58 GF Score
Price kr644.00
GF Value kr1,441.45
Valuation Possible Value Trap
! 9 Warning Signs
View Full Analysis

What is Alvotech Current Accrued Expense?

Alvotech OISE:ALVO -0.92% 58 Current Accrued Expense is kr10,916 Mil as of Jun. 2026. GuruFocus rates OISE:ALVO with a GF Score™ of 58/100 and a GF Value™ of kr1,441.45 (Possible Value Trap). The stock has 9 warning signs investors should review.

Alvotech's Current Accrued Expense for the quarter that ended in Jun. 2026 was kr10,916 Mil.

Alvotech's quarterly Current Accrued Expense declined from Dec. 2025 (kr10,292 Mil) to Mar. 2026 (kr10,018 Mil) but then increased from Mar. 2026 (kr10,018 Mil) to Jun. 2026 (kr10,916 Mil).

Alvotech's annual Current Accrued Expense declined from Dec. 2023 (kr6,788 Mil) to Dec. 2024 (kr6,398 Mil) but then increased from Dec. 2024 (kr6,398 Mil) to Dec. 2025 (kr10,292 Mil).

Alvotech Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Alvotech's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alvotech Current Accrued Expense Chart

Alvotech Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial 4,184.25 4,436.07 6,787.77 6,398.22 10,291.86

Alvotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7,858.08 0.00 10,291.86 10,018.46 10,916.49
OISE:ALVO
58GF Score
Alvotech OISE:ALVO
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alvotech Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of kr10,916 Mil mean?
Alvotech (OISE:ALVO) has a Current Accrued Expense of kr10,916 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Alvotech and its competitors.
Is Alvotech's Current Accrued Expense too high?
Alvotech's current Current Accrued Expense is kr10,916 Mil. Overall, Alvotech has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Alvotech's Current Accrued Expense compare to ETON and ANIP?
Alvotech's Current Accrued Expense of kr10,916 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Drug Manufacturers company?
A good Current Accrued Expense depends on the Drug Manufacturers industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Alvotech and its competitors. Alvotech's current Current Accrued Expense is kr10,916 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alvotech stock overvalued right now?
Based on GuruFocus' analysis, Alvotech (OISE:ALVO) is currently considered Possible Value Trap. The stock's GF Value™ is kr1,441.45, compared to a current price of kr644.00 — trading 55.3% below its estimated fair value. The current Current Accrued Expense is kr10,916 Mil. Alvotech's overall GF Score™ is 58/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Alvotech (OISE:ALVO), the current Current Accrued Expense is kr10,916 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alvotech (OISE:ALVO) Overvalued in 2026?

Based on GuruFocus' analysis, Alvotech stock appears to be undervalued. The current stock price of kr644.00 is trading 55.3% below its estimated GF Value™ of kr1,441.45. GuruFocus considers Alvotech to be Possible Value Trap.

Key valuation signals for OISE:ALVO:

  • Current Accrued Expense: kr10,916 Mil
  • GF Value™: kr1,441.45 vs. price of kr644.00 (55.3% below fair value)
  • GF Score™: 58/100 with 9 warning signs

No single metric tells the full story. See the OISE:ALVO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alvotech Business Description

Other Exchanges ALVO:USAZ45:Germany
Address 9, rue de Bitbourg, Luxembourg, LUX, L-1273
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
58GF Score

Get the complete analysis for OISE:ALVO

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr644.00
Price
kr1,441.45
GF Value